Zemfirza (cediranib maleate)
- Region
- 🇪🇺 EU
- Active substance
- cediranib maleate
- Company
- AstraZeneca AB
- Status
- Application withdrawn
- Therapeutic area
- Ovarian Neoplasms
- Application
- EMEA/H/C/004003
- ATC
- L01XE32
- Official record
- www.ema.europa.eu
Indication
Treatment of platinum sensitive relapsed (PSR) ovarian cancer
Regulatory milestones
No milestones recorded in the last year.
Follow Zemfirza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.